06/22/22 4:05 PMNasdaq : TERN clinical triallow floatTerns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022-Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant dose-dependent effects on key target engagement biomarkers -Additional presentations to detail clinical data from Tern’s extensive pipeline, includingRHEA-AIneutral
06/08/22 4:05 PMNasdaq : TERN conferencesclinical triallow floatTerns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such asRHEA-AIneutral
06/01/22 4:05 PMNasdaq : TERN managementlow floatTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical OfficerTerns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-moleculeRHEA-AIneutral
05/16/22 4:05 PMNasdaq : TERN earningslow floatTerns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates-IND opened for NASH Phase 2a trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist); trial initiated with top-line data expected in second half of 2023 -TERN-601 (GLP-1R agonist) IND-enabling studies underway; Phase 1 clinical trial initiation for obesity expectedRHEA-AIneutral
04/04/22 4:05 PMNasdaq : TERN conferenceslow floatTerns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare ConferenceTerns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such asRHEA-AIneutral
03/21/22 4:05 PMNasdaq : TERN clinical triallow floatTerns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such asRHEA-AIvery negative
03/03/22 4:05 PMNasdaq : TERN earningslow floatTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights-Top-line data readout from TERN-201 (VAP-1 inhibitor) clinical trial in NASH expected in March 2022 -Initiation of Terns’ first NASH trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist) planned for first half of 2022 with top-line data expected in second half ofRHEA-AInegative
02/28/22 4:05 PMNasdaq : TERN conferenceslow floatTerns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare ConferenceTerns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such asRHEA-AIneutral
01/06/22 7:05 AMNasdaq : TERN managementlow floatTerns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development OfficerTerns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such asRHEA-AIpositive
01/03/22 4:05 PMNasdaq : TERN conferenceslow floatTerns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care ConferenceTerns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such asRHEA-AIneutral